Click here - to use the wp menu builder

about fansalaran

FanSalaran is a comprehensive media platform dedicated to reporting and clarifying the significant achievements of pharmaceutical companies. In collaboration with passionate and motivated young journalists, this website consistently strives to showcase the country's successes in order to inspire and encourage the hardworking individuals of this land.

Picsart_24-10-31_14-45-38-363-696x391 — {"remix_data":[],"remix_entry_point":"challenges","source_tags":["local"],"origin":"unknown","total_draw_time":0,"total_draw_actions":0,"layers_used":0,"brushes_used":0,"photos_added":0,"total_editor_actions":{},"tools_used":{"square_fit":1},"is_sticker":false,"edited_since_last_sticker_save":true,"containsFTESticker":false}

pharma news

Less than 1 min.Read

“Reduction of Brain Inflammation with Gradual Dosing of Kisunla”

November 1, 2024

According to current results from a final phase study, the Alzheimer’s drug Kisunla, developed by Eli Lilly, reduces the percentage of patients experiencing potentially serious brain swelling with a more gradual dosing regimen.

**Lilly’s Statement:**
The reduction of toxic amyloid plaques with the standard dose of Kisunla, known scientifically as donanemab, is comparable. The company intends to submit the results to various regulatory agencies to update the labeling.

Hot this week